European health regulators said on Friday they had recommended approval of a drug for advanced lung cancer developed by Swiss drugmaker Novartis that is intended to treat patients with a specific genetic mutation. It is designed for use in non-small cell lung cancer patients who have previously been treated with Pfizer's Xalkori, another ALK inhibitor. Between 2 and 7 percent of non-small cell lung cancer patients have the specific mutation of the ALK (anaplastic lymphoma kinase) protein for which such treatment is targeted.
via Health News Headlines - Yahoo News
Read More Here..
No comments:
Post a Comment